Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma
Interventions: DRUG: Capecitabine|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pembrolizumab
Sponsor: Northwestern University
Collaborators: Merck Sharp & Dohme LLC|National Cancer Institute (NCI)